Access EIS investments for December 2022 and January 2023
SyndicateRoom logo
Syndicate Room
6 February 20232 min read
Between December and January, we added three new startups to the Access EIS portfolio, investing alongside super angels in each case (for more on our super angels, and our co-investment model, see our [dedicated page](/invest/angel-investors). Find out more about our fund, [Access EIS](/invest), or read about our new portfolio companies below. ### Incard Incard is a payment solution designed exclusively for e-commerce, entrepreneurs, dropshippers and influencers. It facilitates faster international payments, allows the issue of virtual cards for employees and integrates with digital platforms. It also comes with built-in accounting software as part of the Incard app. Incard Our angel partner in the round has an IRR of 44% and has invested into Hadean, Converge and AimBrain among others. **Total Round:** approx.£750,000. **Stage** Pre-revenue. [Visit website](https://www.incard.co/)
### Five Alarm Bio Five Alarm Bio develops anti-ageing therapeutics designed to help extend the lifecycle of cells and to avoid illnesses associated with ageing. 5 alarm bio Our angel partner in the round has an weighted IRR of 66% and has invested into Geospock, Healx and Gelmetix among others. **Total Round:** approx. £510,000. **Stage** Pre-revenue. [Visit website](http://www.fivealarmbio.com/)
### Itza Itza develops software and offers educational services with the aim of making online and digital learning more engaging. Its first product, GET SET, is currently in beta. Itza Our angel partner in the round has an weighted IRR of 33% and has invested into Unmind, Percent and The Car Finance Company among others. **Total Round:** approx. £3,000,000. **Stage** Pre-revenue. [Visit website](https://www.itza.io/)
Award
What is Access EIS?
Read our fund brochure for everything you need to know about Access, from the specifics of our innovative co-investment model to our fees, and how to invest.
Risk warning: Please click here to read the full risk warning.
Investing in early-stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. Tax relief depends on an individual’s circumstances and may change in the future. In addition, the availability of tax relief depends on the company invested in maintaining its qualifying status. Past performance is not a reliable indicator of future performance. You should not rely on any past performance as a guarantee of future investment performance.
This page has been approved as a financial promotion by Syndicate Room Ltd, which is authorised and regulated by the Financial Conduct Authority (No. 613021).
We use cookies to improve our service. By continuing to use this site you are agreeing to their use. Find out more.
Please provide your email and/or phone number and we'll get back to you as soon as possible.

Important information

Investments of this nature carry risks to your capital and are illiquid. Tax reliefs depend on individual circumstances, and are subject to change and status. Investments should only be made on consideration of the full Information Memorandum and the detailed risk factors contained therein. Please select your investor type below.

Financial Adviser
High Net Worth Investor
Sophisticated Investor
Restricted Investor
Professional Investor